Literature DB >> 2044569

Imaging pattern of radiolabelled lymphokine-activated killer cells in patients with metastatic malignant melanoma.

E Schäfer1, R Dummer, C Eilles, W Börner, R Martin, J Rendl, G Burg.   

Abstract

In patients with metastatic malignant melanoma the distribution patterns of radiolabelled lymphokine-activated killer (LAK) cells were investigated. Peripheral mononuclear cells (PMC) were isolated from six patients. LAK cells were generated by culturing PMC in complete medium containing 1000 U interleukin (IL)-2/ml and labelled with indium 111 before retransfer. We obtained scans at 2.5, 24, 48 or 96 h after injection with a high resolution gamma-camera. Intravenously injected LAK cells distributed to the lungs, liver, spleen and bone marrow. External tumour detection of known lymph node and bone metastases was successful in four. It failed in one patient with a solitary lung metastasis and in another patient with subcutaneous metastases. Our results suggest that LAK cells show tumour homing, providing a direct interaction between tumour and cytotoxic cells. We conclude that PMC seem to retain their ability to migrate after IL-2 stimulation and 111In-labeling. This technique may be helpful for kinetics studies or external detection of metastases in patients with malignant melanoma.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2044569     DOI: 10.1007/bf00950755

Source DB:  PubMed          Journal:  Eur J Nucl Med        ISSN: 0340-6997


  15 in total

1.  An experimental comparison of radioactive labels with potential application to lymphocyte migration studies in patients.

Authors:  G H Rannie; M L Thakur; W L Ford
Journal:  Clin Exp Immunol       Date:  1977-09       Impact factor: 4.330

2.  Survey of radioactive agents for in vitro labeling of phagocytic leukocytes. I. Soluble agents.

Authors:  J G McAfee; M L Thakur
Journal:  J Nucl Med       Date:  1976-06       Impact factor: 10.057

3.  A method for following human lymphocyte traffic using indium-111 oxine labelling.

Authors:  J Wagstaff; C Gibson; N Thatcher; W L Ford; H Sharma; W Benson; D Crowther
Journal:  Clin Exp Immunol       Date:  1981-03       Impact factor: 4.330

4.  Cell damage resulting from the labeling of rat lymphocytes and HeLa S3 cells with In-111 oxine.

Authors:  P M Chisholm; H J Danpure; G Healey; S Osman
Journal:  J Nucl Med       Date:  1979-12       Impact factor: 10.057

5.  Imaging pattern of previously in vitro sensitized and interleukin-2 expanded autologous lymphocytes in human cancer.

Authors:  B Mukherji; O Arnbjarnarson; L A Spitznagle; R I Kalish; J Hoffman; M T Ergin; R P Spencer
Journal:  Int J Rad Appl Instrum B       Date:  1988

6.  In vivo distribution and tissue localization of highly purified rat lymphokine-activated killer (LAK) cells.

Authors:  A A Maghazachi; R B Herberman; N L Vujanovic; J C Hiserodt
Journal:  Cell Immunol       Date:  1988-08       Impact factor: 4.868

7.  Human lymphocyte traffic assessed by indium-111 oxine labelling: clinical observations.

Authors:  J Wagstaff; C Gibson; N Thatcher; W L Ford; H Sharma; D Crowther
Journal:  Clin Exp Immunol       Date:  1981-03       Impact factor: 4.330

8.  Tumor-derived interleukin-2-dependent lymphocytes in adoptive immunotherapy of lung cancer.

Authors:  R L Kradin; L A Boyle; F I Preffer; R J Callahan; M Barlai-Kovach; H W Strauss; S Dubinett; J T Kurnick
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

9.  Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study.

Authors:  S L Topalian; D Solomon; F P Avis; A E Chang; D L Freerksen; W M Linehan; M T Lotze; C N Robertson; C A Seipp; P Simon
Journal:  J Clin Oncol       Date:  1988-05       Impact factor: 44.544

10.  Tumor localization of adoptively transferred indium-111 labeled tumor infiltrating lymphocytes in patients with metastatic melanoma.

Authors:  B Fisher; B S Packard; E J Read; J A Carrasquillo; C S Carter; S L Topalian; J C Yang; P Yolles; S M Larson; S A Rosenberg
Journal:  J Clin Oncol       Date:  1989-02       Impact factor: 44.544

View more
  6 in total

1.  Monitoring of a new approach of immunotherapy with allogenic (111)In-labelled NK cells in patients with renal cell carcinoma.

Authors:  Birgit Meller; Christoph Frohn; Jörg-Matthias Brand; Isabel Lauer; Lutz F Schelper; Katharina von Hof; Holger Kirchner; Eckart Richter; Manfred Baehre
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-12-19       Impact factor: 9.236

Review 2.  A role for gamma scintigraphy in cancer immunology and immunotherapy.

Authors:  A C Perkins; M V Pimm
Journal:  Eur J Nucl Med       Date:  1992

3.  Nuclear medicine 2000.

Authors:  O Schober
Journal:  Eur J Nucl Med       Date:  1992

Review 4.  Non-invasive cell tracking in cancer and cancer therapy.

Authors:  Hao Hong; Yunan Yang; Yin Zhang; Weibo Cai
Journal:  Curr Top Med Chem       Date:  2010       Impact factor: 3.295

5.  Noninvasive imaging of cell-mediated therapy for treatment of cancer.

Authors:  Elizabeth J Akins; Purnima Dubey
Journal:  J Nucl Med       Date:  2008-06       Impact factor: 10.057

Review 6.  Present status and future trends in molecular imaging of lymphocytes.

Authors:  Chiara Lauri; Michela Varani; Valeria Bentivoglio; Gabriela Capriotti; Alberto Signore
Journal:  Semin Nucl Med       Date:  2022-09-20       Impact factor: 4.802

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.